Bayer entered an exclusive global license and collaboration agreement with Kumquat Biosciences to develop and commercialize Kumquat’s KRAS G12D inhibitor, a precision oncology asset targeting pancreatic, colorectal, and lung cancers harboring this prevalent oncogenic variant. The deal carries potential payments exceeding $1.3 billion and positions Bayer to expand its oncology pipeline with this first-in-class candidate. Kumquat retains responsibilities for initiating early clinical studies, with Bayer overseeing subsequent development and commercialization. This partnership reflects the intensifying focus on KRAS-targeted therapies following recent FDA approvals of inhibitors for other KRAS mutations and highlights the clinical unmet need for effective G12D inhibitors.